These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15291425)

  • 1. [Prevention of cardiovascular complications after a stroke or TIA: hypotensive and hypocholesterolemic therapy].
    Vahl AC
    Ned Tijdschr Geneeskd; 2004 Jul; 148(28):1408; author reply 1408-9. PubMed ID: 15291425
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prevention of cardiovascular complications after a stroke or TIA: hypotensive and hypocholesterolemic therapy].
    Dippel DW; van der Worp HB
    Ned Tijdschr Geneeskd; 2004 Apr; 148(17):820-4. PubMed ID: 15141647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving prescribing practices in primary care. A randomised trial and economic analysis of a multicomponent intervention showed small, but important, gains.
    Del Mar C
    PLoS Med; 2006 Jun; 3(6):e229. PubMed ID: 16729845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic factors in formulating a national policy on the prevention by drugs of cardiovascular disease.
    Malcolm L
    N Z Med J; 1990 Aug; 103(896):402-4. PubMed ID: 2117264
    [No Abstract]   [Full Text] [Related]  

  • 5. Orphans of best prevention.
    Rubba P
    Nutr Metab Cardiovasc Dis; 2007 Sep; 17(7):483-5. PubMed ID: 17628457
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiovascular risk calculators: understanding differences and realising economic implications.
    Quaglini S; Stefanelli M; Boiocchi L; Campari F; Cavallini A; Micieli G
    Stud Health Technol Inform; 2003; 95():617-22. PubMed ID: 14664056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Considerations in the treatment of mild-to-moderate hypertension.
    Giaquinta D
    Manag Care Interface; 2001 Mar; 14(3):80-1. PubMed ID: 11301960
    [No Abstract]   [Full Text] [Related]  

  • 8. [Research and marketing].
    Meland E; Hernborg A
    Tidsskr Nor Laegeforen; 2004 Jul; 124(13-14):1820. PubMed ID: 15229677
    [No Abstract]   [Full Text] [Related]  

  • 9. Secondary-prevention drug prescription in the very elderly after ischemic stroke or TIA.
    Ovbiagele B; Hills NK; Saver JL; Johnston SC
    Neurology; 2006 Feb; 66(3):313-8. PubMed ID: 16476928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economics of drug treatment.
    Jackson PR
    Lancet; 2002 Mar; 359(9309):892-3. PubMed ID: 11897317
    [No Abstract]   [Full Text] [Related]  

  • 11. Eprosartan in secondary prevention of stroke: the economic evidence.
    Wessels F
    Cardiovasc J Afr; 2007; 18(2):95-6. PubMed ID: 17497046
    [No Abstract]   [Full Text] [Related]  

  • 12. Commentary: The challenge of prevention in China.
    McGhee SM; Hedley AJ
    Int J Epidemiol; 2010 Feb; 39(1):254-5. PubMed ID: 20056766
    [No Abstract]   [Full Text] [Related]  

  • 13. Implications of stroke prevention trials: treatment of global risk.
    Elkind MS
    Neurology; 2005 Jul; 65(1):17-21. PubMed ID: 16009880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Secondary prevention of recurrent stroke by lowering cholesterol levels and blood pressure].
    Lodder J; van Oostenbrugge R; Boreas A; Limburg M
    Ned Tijdschr Geneeskd; 2006 Nov; 150(47):2622; author reply 2622-3. PubMed ID: 17203705
    [No Abstract]   [Full Text] [Related]  

  • 15. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
    Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
    Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [SBU should investigate what is an evidence-based and cost-effective use of statins].
    Hjemdahl P; Allhammar A; Heaton C; Hulting J; Kahan T; Malmström R; Martinsson A; Rücker F; Schenck-Gustafsson K; Schwieler J; Törnerud M; Wettermark B
    Lakartidningen; 2009 Aug 5-18; 106(32-33):1992-4. PubMed ID: 19764381
    [No Abstract]   [Full Text] [Related]  

  • 17. [Cardiovascular prevention: not necessary under the age of 40].
    Walma EP
    Ned Tijdschr Geneeskd; 2009; 153():B351. PubMed ID: 19785804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
    Hennekens CH; Schneider WR
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study.
    Marshall T
    Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):523-8. PubMed ID: 16874140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated control of hypertension, dyslipidemia and carotid atherosclerosis in the reduction of cardiovascular risk.
    Riccioni G
    Expert Rev Cardiovasc Ther; 2007 May; 5(3):371-4. PubMed ID: 17489661
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.